Exploratory Open Label Study of GM-CSF Coding Oncolytic Adenovirus CGTG-102, With Low Dose Cyclophosphamide in Patients With Refractory Injectable Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2016
At a glance
- Drugs ONCOS 102 (Primary) ; ONCOS 102 (Primary) ; Cyclophosphamide
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Oncos Therapeutics
- 09 Jun 2016 Results published in Targovax media release.
- 05 Nov 2015 According to an Oncos media release, results from this trial will be presented at the SITC 2015 - an annual event of The Society for Immunotherapy of Cancer.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.